Otsuka reports 27% revenue growth in Rexulti in 1H24. The company raised 2024 sales and business profit guidance. Acquisition of Jnana Therapeutics will further strengthen specialty portfolio.
What is covered in the Full Insight:
1H24 Results Overview
Pharmaceutical Segment Performance
Revised 2024 Guidance
Acquisition of Jnana Therapeutics
Future Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.